Kinesiophobia, Quality of Life, and Cognitive Functions in Fibromyalgia Syndrome

Sponsor
Bozyaka Training and Research Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04695288
Collaborator
(none)
160
1
18.7
8.5

Study Details

Study Description

Brief Summary

Although one of the most evidence-based treatment protocols is based on exercise strategies in patients with Fibromyalgia Syndrome, fear and avoidance of physical activity; named 'Kinesiophobia' may hinder the patients from the exercises. Cognitive dysfunctions are seen frequently in Fibromyalgia Syndrome. The aim of this study, to assess the relationship between kinesiophobia and cognitive functions, disease severity, quality of life, physical activity level, pain intensity, and anxiety/depression level in Fibromyalgia patients. Additionally, the investigators aimed to compare the kinesiophobia level and cognitive functions between patients with Fibromyalgia Syndrome and control subjects.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Cognitive dysfunction, including learning difficulties, memory, attention, and executive dysfunctions are frequent in fibromyalgia syndrome. Kinesiophobia is defined as fear and avoidance of physical activities, and it can lead to increased disability in patients with chronic pain. Although there is a relationship between cognitive functions and physical performance in Fibromyalgia Syndrome, the relationship between kinesiophobia, fibrofog, and quality of life are required to be investigated.

    The aims of this study are:
    1. To compare the kinesiophobia and cognitive functions in Fibromyalgia Syndrome with healthy volunteers

    2. To examine the relationship between the severity of kinesiophobia, cognitive functions, disease activity, quality of life, physical activity level, depression and anxiety severity in Fibromyalgia Syndrome.

    The hypothesis is, the patients diagnosed with Fibromyalgia Syndrome have higher kinesiophobia severity and worse cognitive functions, and also that kinesiophobia severity is associated with cognitive dysfunction, disease severity, physical activity level, and psychiatric symptoms in patients with Fibromyalgia Syndrome.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    160 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    Relationship Between Kinesiophobia, Quality of Life, and Cognitive Functions in Fibromyalgia Syndrome
    Actual Study Start Date :
    Jan 1, 2021
    Actual Primary Completion Date :
    Jul 25, 2022
    Actual Study Completion Date :
    Jul 25, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Fibromyalgia Syndrome

    100 participants with a diagnosis of Fibromyalgia Syndrome according to the 2016 revised American College of Rheumatology diagnostic criteria.

    Control subjects

    60 healthy participants do not meet the exclusion criteria of the study.

    Outcome Measures

    Primary Outcome Measures

    1. TAMPA Kinesiophobia Scale [1 year]

      The TAMPA Kinesiophobia Scale consists of 17 questions. Each question is scored between 1-4. The maximum score is 68, with high scores indicating an increased severity of kinesiophobia. A score of more than 37 indicates high severity of kinesiophobia.

    2. Montreal Cognitive Assessment Test [1 year]

      This test evaluates eight separate cognitive functions: Attention, working memory, short-term memory, delayed memory, visuospatial abilities, executive functioning, language, and orientation to time and place. Scores of 21 and above are considered normal, with the highest test score being 30.

    Secondary Outcome Measures

    1. Visual Analogue scale [1 year]

      The patient is asked to mark her severity of pain on a horizontal 10-cm line with number 0 on one end representing "no" and number 10 on the other end indicating "very severe pain". Higher scores indicate higher levels of pain intensity.

    2. Fibromyalgia Impact Questionnaire [1 year]

      It aims to evaluate the arthritis symptoms and functional status of patients with fibromyalgia syndrome through 21 questions that inquire about physical functions, work-related situations, depression, anxiety, waking up tired, pain, stiffness, and fatigue. Higher scores indicate greater impact of fibromyalgia on functioning. Final score should range from 0 to 80.

    3. Short Form-36 [1 year]

      Short Form-36 (SF-36) is a widely used and validated scale for evaluating the quality of life. It is not specific to any disease group. It consists of thirty six items. It consists of 8 subscales related to physical health (physical function, physical role, pain, general health) and mental health (energy, social function, emotional role difficulty, mental health) factors. Each sub-scale chart is evaluated between 0 and 100 points. Higher scores indicate good health.

    4. International Physical Activity Questionnaire-Short Form [1 year]

      Physical activity levels in the last 7 (seven) days will be evaluated with the International Physical Activity Questionnaire-Short form. This short form consists of seven questions and provides information about the durations of physical activities, walking and sitting within the last seven days in the metabolic equivalent (MET)-min/week unit.

    5. Hospital Anxiety/ Depression Questionnaire [1 year]

      Hospital Anxiety/ Depression Questionnaire determines the risk in terms of anxiety and depression in the patient and to measure its level and severity. It is used to diagnose anxiety and depression in a short time and determine the risk group for patients with physical diseases and those who apply to primary health care. Seven (odd numbers) of 14 questions measure anxiety and seven (even numbers) measure depression. Answers are scored in a four-point Likert scale between 0 and 3. The lowest score that patients can get from both subscales is 0, the highest score is 21.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    -Fibromyalgia Syndrome

    Exclusion Criteria:
    • Education year < 5

    • Inflammatory rheumatic disease

    • Malignancy

    • Psychiatric disease

    • Alcohol/substance addiction

    • Central nervous system disease

    • History of head trauma

    • Chronic pain conditions other than Fibromyalgia Syndrome

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Health Sciences Izmir Bozyaka Training and Research Hospital Izmir Karabaglar Turkey

    Sponsors and Collaborators

    • Bozyaka Training and Research Hospital

    Investigators

    • Principal Investigator: Elcin Ergez, MD, University of Health Sciences Izmir Bozyaka Training and Research Hospital
    • Study Director: Seniz Akcay, Assoc Prof, University of Health Sciences Izmir Bozyaka Training and Research Hospital
    • Study Chair: Nesibe Dogan, Specialist, University of Health Sciences Izmir Bozyaka Training and Research Hospital
    • Study Chair: Dursun Hakan Delibas, Specialist, University of Health Sciences Izmir Bozyaka Training and Research Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Şeniz Akçay, Study Director, Bozyaka Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT04695288
    Other Study ID Numbers:
    • 01/12/2020-297
    First Posted:
    Jan 5, 2021
    Last Update Posted:
    Aug 3, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Şeniz Akçay, Study Director, Bozyaka Training and Research Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 3, 2022